Carl A Gregory
Overview
Explore the profile of Carl A Gregory including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
2656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Doucet D, Brubaker C, Turner D, Gregory C
Front Oncol
. 2023 Apr;
13:1114822.
PMID: 37007131
Background: The canonical Wnt inhibitor Dickkopf-1 (Dkk-1) has the capacity to modulate homeostasis between canonical and non-canonical Wnt pathways and also signal independently of Wnt. The specific effects of Dkk-1...
12.
Benavides O, Gibbs H, White B, Kaunas R, Gregory C, Walsh A, et al.
PLoS One
. 2023 Mar;
18(3):e0282298.
PMID: 36976801
The adoption of cell-based therapies into the clinic will require tremendous large-scale expansion to satisfy future demand, and bioreactor-microcarrier cultures are best suited to meet this challenge. The use of...
13.
MacIver M, Dobson L, Gregory C, Muneoka K, Saunders W
PLoS One
. 2022 Jun;
17(6):e0269571.
PMID: 35679245
The dog is an underrepresented large animal translational model for orthopedic cell-based tissue engineering. While chondrogenic differentiation of canine multipotent stromal cells (cMSCs) has been reported using the classic micromass...
14.
Brokesh A, Cross L, Kersey A, Murali A, Richter C, Gregory C, et al.
Sci Adv
. 2022 Apr;
8(17):eabl9404.
PMID: 35476448
Bioactive materials harness the body's innate regenerative potential by directing endogenous progenitor cells to facilitate tissue repair. Dissolution products of inorganic biomaterials provide unique biomolecular signaling for tissue-specific differentiation. Inorganic...
15.
Gregory C, Lee R, Liu F, Alge D
Front Bioeng Biotechnol
. 2022 Apr;
10:873375.
PMID: 35372300
No abstract available.
16.
Pan S, Cesarek M, Godoy C, Co C, Schindler C, Padilla K, et al.
Br J Cancer
. 2022 Mar;
127(1):43-55.
PMID: 35277659
Background: Osteosarcoma (OS) is the most common primary bone malignancy. Chemotherapy plays an essential role in OS treatment, potentially doubling 5-year event-free survival if tumour necrosis can be stimulated. The...
17.
Dobson L, Zeitouni S, Mcneill E, Bearden R, Gregory C, Saunders W
Front Bioeng Biotechnol
. 2021 Nov;
9:764703.
PMID: 34796168
Novel bone regeneration strategies often show promise in rodent models yet are unable to successfully translate to clinical therapy. Sheep, goats, and dogs are used as translational models in preparation...
18.
Rogers R, Haskell A, White B, Dalal S, Lopez M, Tahan D, et al.
Stem Cells Transl Med
. 2021 Sep;
10(12):1650-1665.
PMID: 34505405
Human mesenchymal stem cells (hMSCs) are effective in treating disorders resulting from an inflammatory or heightened immune response. The hMSCs derived from induced pluripotent stem cells (ihMSCs) share the characteristics...
19.
Mota S, Rogers R, Haskell A, Mcneill E, Kaunas R, Gregory C, et al.
J Med Imaging (Bellingham)
. 2021 Feb;
8(1):014503.
PMID: 33542945
: Mesenchymal stem cells (MSCs) have demonstrated clinically relevant therapeutic effects for treatment of trauma and chronic diseases. The proliferative potential, immunomodulatory characteristics, and multipotentiality of MSCs in monolayer culture...
20.
Gasson S, Dobson L, Chow L, Dow S, Gregory C, Saunders W
Stem Cells Dev
. 2020 Dec;
30(4):214-226.
PMID: 33356875
A growing body of work suggests that canine mesenchymal stromal cells (cMSCs) require additional agonists such as bone morphogenic protein-2 (BMP-2) for consistent in vitro osteogenic differentiation. BMP-2 is costly...